Comparison of admission random glucose, fasting glucose, and glycated hemoglobin in predicting the neurological outcome of acute ischemic stroke: A retrospective study

Jia-Ying Sung  1, 2,  
Chin-I Chen  1, 2,  
Yi-Chen Hsieh  3,  
Yih-Ru Chen  4,  
Hsin-Chiao Wu  4,  
Lung Chan  2, 5,  
Chaur-Jong Hu  2, 5,  
Han-Hwa Hu  2, 5,  
Hung-Yi Chiou  4,  
Nai-Fang Chi  2, 5  
Corresp.  2, 5

1  Department of Neurology, Wang Fang Hospital, Taipei, Taiwan  
2  Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan  
3  The PhD Program of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan  
4  School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan  
5  Department of Neurology, Shuang Ho Hospital, New Taipei City, Taiwan

Corresponding Author: Nai-Fang Chi  
Email address: naifangchi@tmu.edu.tw

Background. Hyperglycemia is a known predictor of negative outcomes in stroke. Several glycemic measures, including admission random glucose, fasting glucose, and glycated hemoglobin (HbA1c), have been associated with bad neurological outcomes in acute ischemic stroke, particularly in nondiabetic patients. However, the predictive power of these glycemic measures is yet to be investigated.

Methods. This retrospective study enrolled 484 patients with acute ischemic stroke from January 2009 to March 2013, and complete records of initial stroke severity, neurological outcomes at 3 months, and glycemic measures were evaluated. We examined the predictive power of admission random glucose, fasting glucose, and HbA1c for neurological outcomes in acute ischemic stroke. Furthermore, subgroup analyses of nondiabetic patients and patients with diabetes were performed separately.

Results. Receiver operating characteristic (ROC) analysis revealed that admission random glucose and fasting glucose were significant predictors of poor neurological outcomes, whereas HbA1c was not [areas under the ROC curve (AUCs): admission random glucose = 0.564, \( p = 0.026 \); fasting glucose = 0.598, \( p = 0.001 \); HbA1c = 0.510, \( p = 0.742 \)]. Subgroup analyses of nondiabetic patients and those with diabetes revealed that only fasting glucose predicts neurological outcomes in patients with diabetes, and the AUCs of these three glycemic measures did not differ between the two groups. A multivariate logistic regression analysis of the study patients indicated that only age, initial stroke severity, and fasting glucose were independent predictors of poor neurological outcomes, whereas admission random glucose and HbA1c were not (adjusted odds ratio: admission random glucose = 1.002, \( p = 0.228 \); fasting glucose = 1.005, \( p = 0.039 \); HbA1c = 1.160, \( p = 0.076 \)). Furthermore, subgroup multivariate logistic regression analyses of nondiabetic patients and those with diabetes indicated that none of the three glycemic measures were associated with poor neurological outcomes.

Discussion. Fasting glucose is an independent predictor of poor neurological outcomes in patients with acute ischemic stroke and had greater predictive power than that of admission random glucose and HbA1c. The predictive power of glycemic measures for poor neurological outcomes did not differ significantly between the nondiabetic patients and those with diabetes.
Title
Comparison of admission random glucose, fasting glucose, and glycated hemoglobin in predicting the neurological outcome of acute ischemic stroke- A retrospective study

Short Title
Hyperglycemia in acute ischemic stroke

Authors
Jia-Ying Sung1,2, Chin-I Chen1,2, Yi-Chen Hsieh3, Yih-Ru Chen4, Hsin-Chiao Wu4, Lung Chan2,5, Chaur-Jong Hu2,5, Han-Hwa Hu2,5, Hung-Yi Chiou4, and Nai-Fang Chi2,5

1 Department of Neurology, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan
2 Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
3 The PhD Program of Neural Regenerative Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
4 School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan
5 Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

Correspondence to:
Nai-Fang Chi
Department of Neurology, Taipei Medical University Shuang Ho Hospital, 291, Zhongzheng Road, Zhonghe District, New Taipei City, Taiwan.
E-mail address: naifangchi@tmu.edu.tw
ABSTRACT

Background. Hyperglycemia is a known predictor of negative outcomes in stroke. Several glycemic measures, including admission random glucose, fasting glucose, and glycated hemoglobin (HbA1c), have been associated with bad neurological outcomes in acute ischemic stroke, particularly in nondiabetic patients. However, the predictive power of these glycemic measures is yet to be investigated.

Methods. This retrospective study enrolled 484 patients with acute ischemic stroke from January 2009 to March 2013, and complete records of initial stroke severity, neurological outcomes at 3 months, and glycemic measures were evaluated. We examined the predictive power of admission random glucose, fasting glucose, and HbA1c for neurological outcomes in acute ischemic stroke. Furthermore, subgroup analyses of nondiabetic patients and patients with diabetes were performed separately.

Results. Receiver operating characteristic (ROC) analysis revealed that admission random glucose and fasting glucose were significant predictors of poor neurological outcomes, whereas HbA1c was not [areas under the ROC curve (AUCs): admission random glucose = 0.564, \( p = 0.026 \); fasting glucose = 0.598, \( p = 0.001 \); HbA1c = 0.510, \( p = 0.742 \)]. Subgroup analyses of nondiabetic patients and those with diabetes revealed that only fasting glucose predicts neurological outcomes in patients with diabetes, and the AUCs of these three glycemic measures did not differ between the two groups. A multivariate logistic regression analysis of the study patients indicated that only age, initial stroke severity, and fasting glucose were independent predictors of poor neurological outcomes, whereas admission random glucose and HbA1c were not (adjusted odds ratio: admission random glucose = 1.002, \( p = 0.228 \); fasting glucose = 1.005, \( p = 0.039 \); HbA1c = 1.160, \( p = 0.076 \)). Furthermore, subgroup multivariate logistic regression analyses of nondiabetic patients and those with diabetes indicated that none of the three glycemic measures were associated with poor neurological outcomes.

Discussion. Fasting glucose is an independent predictor of poor neurological outcomes in patients with acute ischemic stroke and had greater predictive power than that of admission random glucose and HbA1c. The predictive power of glycemic measures for poor neurological outcomes did not differ significantly between the nondiabetic patients and those with diabetes.
Introduction

Hyperglycemia may be present in more than half of patients with acute ischemic stroke (Scott et al., 1999). It is associated with an increased risk of infarction volume growth and hemorrhagic transformation (Paciaroni et al., 2009; Parsons et al., 2002), a decreased recanalization rate of thrombolytic therapy (Ribo et al., 2005), and an increased risk of poor neurological outcomes and stroke mortality (Capes et al., 2001). Several indices of hyperglycemia have been reported in stroke: elevated fasting glucose (Yao et al., 2016), elevated admission random glucose (Ahmed et al., 2010; Ribo et al., 2005), maximum glucose during the acute disease stage (Fuentes et al., 2009), and elevated glycated hemoglobin (HbA1c) (Kamouchi et al., 2011; Lattanzi et al., 2016). The levels of fasting glucose, admission random glucose, and maximum glucose have been associated with the stress response of stroke, particularly in nondiabetic patients (Capes et al., 2001; Stead et al., 2009), and HbA1c was considered as a marker for prestroke glycemic control (Kamouchi et al., 2011). Moreover, some studies have reported that in acute ischemic stroke, hyperglycemia is more detrimental in nondiabetic patients than in those with diabetes (Capes et al., 2001; Stead et al., 2009; Yao et al., 2016). Although these glycemic measures have been associated with neurological outcomes in acute ischemic stroke, the most predictive factor among these is yet to be reported. The present study compared the predictive performance of admission random glucose, fasting glucose, and HbA1c for poor neurological outcomes in acute ischemic stroke. Furthermore,
the predictive performance of these glycemic measures was evaluated through subgroup analysis of patients with diabetes and nondiabetic patients.

Materials & Methods

Study patients

The present study was approved by the Joint Institutional Review Board of Taipei Medical University (No. 201304008). Data were obtained by reviewing medical records of the patients with acute ischemic stroke admitted to the hospitals affiliated with Taipei Medical University, Wan Fang Hospital and Shuang Ho Hospital, between January 2009 and March 2013. Data were included for analysis if the patients were aged ≥20 years, presented to the emergency department with acute ischemic stroke and were subsequently admitted to the neurology department, and complete records of admission random glucose, fasting glucose, HbA1c, National Institute of Health Stroke Scale (NIHSS) scores at admission, and modified Rankin Scale (mRS) scores at 3 months after stroke were obtained. After reviewing the enrolled medical records, patients with a history of stroke or who died or were lost to follow-up within 3 months after stroke were excluded.

Definitions of clinical characteristics and neurological outcomes

In the present study, acute ischemic stroke was confirmed by clinical symptoms and neuroimages.
The etiologic subtype of acute ischemic stroke was classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) study (Adams et al., 1993). Admission random glucose was the first nonfasting plasma glucose measured at the emergency department. Fasting plasma glucose and HbA1c were measured on the first morning of admission after at least 8 hours of fasting.

Hypertension was defined as a systolic blood pressure > 140 mmHg, a diastolic blood pressure > 90 mmHg, or current use of antihypertensive medicines. Diabetes was defined as HbA1c ≥ 6.5% or current use of antidiabetic medicines. Hyperlipidemia was defined as total cholesterol > 200 mg/dL or current use of cholesterol-lowering medicines. Atrial fibrillation was diagnosed according to either a documented history or an electrocardiogram on admission. Initial stroke severity was evaluated on the first day of admission on the basis of the NIHSS at admission, and neurological outcomes were evaluated on the basis of the mRS at 3 months after stroke. Poor neurological outcomes were defined as an mRS score =3, 4, or 5 at 3 months after stroke.

**Statistical analyses**

The continuous variables, rank variables, and proportions of categorical variables were compared between the nondiabetic patients and those with diabetes by using the Student t, Mann–Whitney U, and chi-squared tests, respectively. Receiver operating characteristic (ROC) analysis was conducted for evaluating the predictive performance of the glycemic measures, namely admission
random glucose, fasting glucose, and HbA1c, in distinguishing between the favorable and poor neurological outcomes. Specifically, the predictive performance of these glycemic measures was evaluated by comparing their areas under the ROC curve (AUCs) (DeLong et al., 1988). A univariate logistic regression analysis was conducted to estimate the odds ratio (OR) of poor neurological outcomes for each variable. Age, sex, and variables with \( p \leq 0.2 \) in the univariate logistic regression analysis were included in a multivariate logistic regression model to adjust the OR of poor neurological outcomes for the glycemic measures. Parametric and nonparametric data were expressed as the mean ± standard deviation (SD) and as the median with the interquartile range (IQR), respectively, and \( p < 0.05 \) was considered statistically significant. Statistical data were analyzed using PASW Statistics for Windows version 18.0 (SPSS Inc, Chicago, IL, USA) and MedCalc Statistical Software version 16.8 (MedCalc Software bvba, Ostend, Belgium, https://www.medcalc.org, 2016).

Results

Table 1 summarizes the clinical characteristics of the study patients. Of the 484 patients enrolled in the present study, 212 were nondiabetic and 272 had diabetes. Age, the proportion of hypertension, admission random glucose, and fasting glucose in the patients with diabetes were significantly higher than those in the nondiabetic patients, and the NIHSS score at admission, mRS
score at 3 months after stroke, and proportions of poor neurological outcomes and the stroke etiology subtype did not differ between the two groups.

The AUCs of admission random glucose, fasting glucose, and HbA1c in all patients are presented in Figure 1A. In all patients, admission random glucose and fasting glucose were significant predictors of poor neurological outcomes [AUCs: admission random glucose = 0.564, 95% confidence interval (CI) = 0.519–0.609, \( p = 0.026 \); fasting glucose = 0.598, 95% CI = 0.553–0.642, \( p = 0.001 \)]; however, HbA1c was not a significant predictor (AUC = 0.510, 95% CI = 0.465–0.556, \( p = 0.742 \)). The cutoff values with the highest sensitivity and specificity were 127 mg/dL for admission random glucose (sensitivity = 74.6%, specificity = 39.3%) and 109 mg/dL for fasting glucose (sensitivity = 67.8%, specificity = 51.6%). The AUCs of admission random glucose and fasting glucose did not differ significantly (0.564 vs. 0.598, \( p = 0.194 \)), and the AUCs of admission random glucose and fasting glucose were significantly higher than that of HbA1c (0.564 vs. 0.510, \( p = 0.038 \) and 0.598 vs. 0.510, \( p = 0.001 \), respectively). The ROC curves of admission random glucose, fasting glucose, and HbA1c in the nondiabetic patients (n = 212) and patients with diabetes (n = 272) are presented in Figures 1B and 1C, respectively. In the nondiabetic patients, fasting glucose was not a significant predictor of poor neurological outcomes (AUC = 0.593, 95% CI = 0.524–0.660, \( p = 0.071 \)) with an optimal cutoff value of 109 mg/dL (sensitivity = 39.6%, specificity = 84.8%), whereas admission random glucose and HbA1c were
nonsignificant predictors of poor neurological outcomes (AUCs: admission random glucose = 0.569, 95% CI = 0.499–0.636, \( p = 0.129 \); HbA1c = 0.510, 95% CI = 0.440–0.579, \( p = 0.837 \)). In the patients with diabetes, fasting glucose was a significant predictor of poor neurological outcomes (AUC = 0.596, 95% CI = 0.535–0.655, \( p = 0.014 \)) with an optimal cutoff value of 140 mg/dL (sensitivity = 62.9%, specificity = 54.5%), whereas admission random glucose and HbA1c were nonsignificant predictors of poor neurological outcomes (AUCs: admission random glucose = 0.544, 95% CI = 0.483–0.604, \( p = 0.247 \); HbA1c = 0.503, 95% CI = 0.442–0.564, \( p = 0.948 \)). The AUCs of glycemic measures were not significantly different between the nondiabetic patients and those with diabetes (AUCs: admission random glucose = 0.569 vs. 0.544, \( p = 0.671 \); fasting glucose = 0.593 vs. 0.596, \( p = 0.963 \); HbA1c = 0.510 vs. 0.503, \( p = 0.911 \)).

Table 2 presents the results of univariate and multivariate logistic regression analyses of variables potentially predicting poor neurological outcomes. In univariate logistic regression analysis, age, the NIHSS score at admission, atrial fibrillation, and fasting glucose were significant predictors of poor neurological outcomes in the study patients (crude OR for fasting glucose = 1.005, 95% CI = 1.002–1.008, \( p = 0.003 \)). However, neither admission random glucose nor HbA1c were significant predictors of poor neurological outcomes. The adjusted OR of admission random glucose was determined using multivariate logistic regression model 1, which included age, sex, the NIHSS score at admission, atrial fibrillation, and admission random glucose. Age and the
NIHSS score at admission were significant predictors of poor neurological outcomes, and admission random glucose was not associated with poor neurological outcomes in model 1 (adjusted OR = 1.002, 95% CI = 0.999–1.005, p = 0.228). The adjusted OR for fasting glucose was determined using multivariate logistic regression model 2, which included age, sex, the NIHSS score at admission, atrial fibrillation, and fasting glucose. Age, the NIHSS score at admission, and fasting glucose were significant predictors of poor neurological outcomes in model 2 (adjusted OR for fasting glucose = 1.005, 95% CI = 1.003–1.010, p = 0.039). The adjusted OR of HbA1c was calculated using multivariate logistic regression model 3, which included age, sex, the NIHSS score at admission, atrial fibrillation, and HbA1c. Age and the NIHSS score at admission were significant predictors of poor neurological outcomes, and HbA1c was not associated with poor neurological outcomes in model 3 (adjusted OR = 1.160, 95% CI = 0.985–1.366, p = 0.076).

Subgroup univariate and multivariate logistic regression analyses were performed in the nondiabetic patients and patients with diabetes (Table 2). In the univariate logistic regression analysis, age, the NIHSS score at admission, atrial fibrillation, and fasting glucose were significant predictors of poor neurological outcomes (crude OR for fasting glucose: nondiabetic patients = 1.025, 95% CI = 1.009–1.041, p = 0.002; patients with diabetes = 1.004, 95% CI = 1.001–1.008, p = 0.003). However, after adjustment for the influence of age, sex, the NIHSS score at admission,
and atrial fibrillation, all three glycemic measures were not associated with poor neurological outcomes in both groups.

Discussion
In the present study, of the three glycemic measures, fasting glucose was an independent predictor and the most predictive factor of poor neurological outcomes in patients with acute ischemic stroke. ROC analysis revealed that admission random glucose was a predictor of poor neurological outcomes in all study patients; however, it was not associated with poor neurological outcomes in the logistic regression analysis. Furthermore, ROC and logistic regression analyses revealed that HbA1c was not a predictive factor of poor neurological outcomes. The predictive value of glycemic measures for poor neurological outcomes did not differ significantly between the nondiabetic patients and patients with diabetes.

ROC analysis revealed that fasting glucose and admission random glucose have more predictive value than HbA1c does for poor neurological outcomes in acute ischemic stroke. Studies have reported that a high level of fasting or random glucose is associated with poor neurological outcomes or mortality in acute ischemic stroke (Capes et al., 2001; Fang et al., 2013; Hu et al., 2012), and hyperglycemia at the acute stage of the disease may be largely caused by stress (Douketis, 2002). By contrast, HbA1c represents average glycemic levels in the preceding 6–8
weeks and is not affected by transient hyperglycemia; therefore, HbA1c has been perceived as a marker for prestroke glycemic control (Kamouchi et al., 2011; Lattanzi et al., 2016). Furthermore, HbA1c has been associated with increased mortality (Wu et al., 2014) and poor neurological outcomes (Gao et al., 2016; Hjalmarsson et al., 2014; Lattanzi et al., 2016) in acute ischemic stroke; however, it has also been reported to be nonpredictive of neurological outcomes (Shin et al., 2015). Although many studies have reported the role of hyperglycemia in predicting poor neurological outcomes in acute ischemic stroke, the inclusion criteria for patients, definition of hyperglycemia, and outcome measures varied between these studies; therefore, the results are difficult to compare. Moreover, no study has compared the predictive performance of different definitions of hyperglycemia for neurological outcomes. The results of our study revealed that stress hyperglycemia contributed more than prestroke glycemic control did in predicting negative outcomes in acute ischemic stroke. The ROC analysis revealed that the AUCs of fasting glucose and admission random glucose did not differ significantly; nevertheless, the AUC of fasting glucose was the highest among the three glycemic measures. Furthermore, multivariate logistic regression analysis revealed that fasting glucose was the only independent predictor of poor neurological outcomes among the three glycemic measures (Table 2). Therefore, we speculate that fasting glucose is superior to admission random glucose in predicting neurological outcomes. However, why fasting glucose was more predictive than admission random glucose in this study
remains uncertain, and further investigations are warranted.

Some studies have reported that in acute ischemic stroke, hyperglycemia is more detrimental in nondiabetic patients than in patients with diabetes (Capes et al., 2001; Stead et al., 2009; Yao et al., 2016); however, the present findings are not consistent with the aforementioned results, possibly because of the differences in study designs, statistical methods, definition of hyperglycemia, and functional outcome measures. Most studies have used a cutoff value of blood glucose as the criterion for defining hyperglycemia, such as fasting glucose > 140 mg/dL (Woo et al., 1990) or nonfasting glucose > 130 mg/dL (Stead et al. 2009). However, we used ROC analysis instead of a cutoff value because of the lack of a widely accepted criterion for defining hyperglycemia in acute ischemic stroke. Moreover, ROC analysis enables the comparison of the predictive performance of different glycemic measures and provides information on sensitivity and specificity, which cannot be obtained by defining hyperglycemia on the basis of a cutoff value.

In preclinical animal studies, controlling hyperglycemia with insulin resulted in heterogeneous neuroprotection outcomes (MacDougall & Muir, 2011). In randomized controlled trials of intensive insulin treatment for glycemic control in patients with acute ischemic stroke, there was no difference in death or dependency between the treatment and control groups, and the results were the same in subgroup analyses of patients with diabetes and nondiabetic patients (Bellolio et al., 2014). Therefore, the pathophysiology of hyperglycemia in acute ischemic stroke
probably involves other factors in addition to high blood glucose. Stress-related cytotoxic
neurotransmitters, inflammation, or insulin resistance could be associated with an increased risk
of poor neurological outcomes and mortality in patients with stroke and hyperglycemia (Arenillas
et al., 2007; Harada et al., 2012; Kruyt et al., 2010). The clinical guidelines published by the
American Heart Association/American Stroke Association and the European Stroke Organization
recommend that the glycemic levels of patients with acute ischemic stroke be maintained below
180 mg/dL. This recommendation is based on the consensus of experts because evidence does not
support maintaining the blood glucose at a specific level improves outcomes (European Stroke
Organisation Executive & Committee, 2008; Jauch et al., 2013). Therefore, although
hyperglycemia has been confirmed to be a predictor of negative outcomes in stroke, additional
investigations are warranted for elucidating the underlying mechanisms and treatment strategies.

The present study had some limitations. First, most patients enrolled had mild to moderate
initial stroke severity (median NIHSS score at admission = 4, IQR = 2–8), and the influence of
hyperglycemia might be more prominent in patients with severe stroke. However, only 84 patients
in the present study had an NIHSS score at admission ≥ 10, and a subgroup analysis of these
patients would not have yielded sufficient statistic power. Second, mortality was not included as
an outcome because the timing of and reason for mortality could not be assessed accurately in the
retrospective medical review. Some patients might have died or received follow-up in facilities
other than the two hospitals included in the present study; therefore, the patients who died or were lost to follow-up within 3 months after stroke were not included in this study. Because of the aforementioned limitations, the results of this study cannot be generalized to all ischemic stroke patients. Third, diabetes was defined as HbA1c < 6.5% or as medication usage; therefore, patients with diabetes who were on dietary modification alone with satisfactory HbA1c may have been misclassified as nondiabetic patients.

Conclusions

Fasting glucose is an independent predictor of poor neurological outcomes in patients with acute ischemic stroke, with more predictive power than that of admission random glucose and HbA1c. The predictive value of glycemic measures for poor neurological outcomes in acute ischemic stroke did not differ significantly between the nondiabetic patients and those with diabetes.
References

Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, and Marsh EE, 3rd. 1993. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35-41.

Ahmed N, Davalos A, Eriksson N, Ford GA, Glahn J, Hennerici M, Mikulik R, Kaste M, Lees KR, Lindsberg PJ, Toni D, and Investigators S. 2010. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 67:1123-1130. 10.1001/archneurol.2010.210

Arenillas JF, Moro MA, and Davalos A. 2007. The metabolic syndrome and stroke: potential treatment approaches. Stroke 38:2196-2203. 10.1161/STROKEAHA.106.480004

Bellolio MF, Gilmore RM, and Ganti L. 2014. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev:CD005346. 10.1002/14651858.CD005346.pub4

Capes SE, Hunt D, Malmberg K, Pathak P, and Gerstein HC. 2001. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426-2432.

DeLong ER, DeLong DM, and Clarke-Pearson DL. 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837-845.

Douketis J. 2002. Review: stress hyperglycemia after ischemic stroke indicates a greater risk for death in patients without diabetes. ACP J Club 136:114.

European Stroke Organisation Executive C, and Committee ESOW. 2008. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457-507. 10.1159/000131083

Fang Y, Zhang S, Wu B, and Liu M. 2013. Hyperglycaemia in acute lacunar stroke: a Chinese hospital-based study. Diab Vasc Dis Res 10:216-221. 10.1177/1479164112459663

Fuentes B, Castillo J, San Jose B, Leira R, Serena J, Vivancos J, Davalos A, Nunez AG, Egido J, Diez-Tejedor E, and Stroke Project of the Cerebrovascular Diseases Study Group SSoN. 2009. The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study. Stroke 40:562-568. 10.1161/STROKEAHA.108.519926

Gao Y, Jiang L, Wang H, Yu C, Wang W, Liu S, Gao C, Tong X, Wang J, Jin Y, and Wu J. 2016. Association between Elevated Hemoglobin A1c Levels and the Outcomes of Patients with Small-Artery Occlusion: A Hospital-Based Study. PLoS One 11:e0160223. 10.1371/journal.pone.0160223
Harada S, Fujita-Hamabe W, and Tokuyama S. 2012. Ischemic Stroke and Glucose Intolerance: a Review of the Evidence and Exploration of Novel Therapeutic Targets. *Journal of Pharmacological Sciences* 118:1-13. 10.1254/jphs.11R04CR

Hjalmarsson C, Manhem K, Bokemark L, and Andersson B. 2014. The role of prestroke glycemic control on severity and outcome of acute ischemic stroke. *Stroke Res Treat* 2014:694569. 10.1155/2014/694569

Hu GC, Hsieh SF, Chen YM, Hsu HH, Hu YN, and Chien KL. 2012. Relationship of initial glucose level and all-cause death in patients with ischaemic stroke: the roles of diabetes mellitus and glycated hemoglobin level. *Eur J Neurol* 19:884-891. 10.1111/j.1468-1331.2011.03647.x

Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW, Jr., Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke C, Council on Cardiovascular N, Council on Peripheral Vascular D, and Council on Clinical C. 2013. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 44:870-947. 10.1161/STR.0b013e318284056a

Kamouchi M, Matsuki T, Hata J, Kuwashiro T, Ago T, Sambongi Y, Fukushima Y, Sugimori H, Kitazono T, and Investigators FSR. 2011. Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry. *Stroke* 42:2788-2794. 10.1161/STROKEAHA.111.617415

Kruyt ND, Biessels GJ, Devries JH, and Roos YB. 2010. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. *Nat Rev Neurol* 6:145-155. 10.1038/nrneurol.2009.231

Lattanzi S, Bartolini M, Provinciali L, and Silvestrini M. 2016. Glycosylated Hemoglobin and Functional Outcome after Acute Ischemic Stroke. *J Stroke Cerebrovasc Dis* 25:1786-1791. 10.1016/j.jstrokecerebrovasdis.2016.03.018

MacDougall NJ, and Muir KW. 2011. Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: systematic review and meta-analysis. *J Cereb Blood Flow Metab* 31:807-818. 10.1038/jcbfm.2010.210

Paciaroni M, Agnelli G, Caso V, Corea F, Ageno W, Alberti A, Lanari A, Micheli S, Bertolani L, Venti M, Palmerini F, Billeci AM, Comi G, Previdi P, and Silvestrelli G. 2009. Acute hyperglycaemia and early hemorrhagic transformation in ischemic stroke. *Cerebrovasc Dis* 28:119-123. 10.1159/000223436

Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, and Davis SM. 2002. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance
imaging and spectroscopy study. *Ann Neurol* 52:20-28. 10.1002/ana.10241

Ribo M, Molina C, Montaner J, Rubiera M, Delgado-Mederos R, Arenillas JF, Quintana M, and Alvarez-Sabin J. 2005. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. *Stroke* 36:1705-1709.

Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, and Gray CS. 1999. Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. *Lancet* 353:376-377.

Shin SB, Kim TU, Hyun JK, and Kim JY. 2015. The Prediction of Clinical Outcome Using HbA1c in Acute Ischemic Stroke of the Deep Branch of Middle Cerebral Artery. *Ann Rehabil Med* 39:1011-1017. 10.5535/arm.2015.39.6.1011

Stead LG, Gilmore RM, Bellolio MF, Mishra S, Bhagra A, Vaidyanathan L, Decker WW, and Brown RD, Jr. 2009. Hyperglycemia as an independent predictor of worse outcome in non-diabetic patients presenting with acute ischemic stroke. *Neurocrit Care* 10:181-186. 10.1007/s12028-008-9080-0

Woo J, Lam CW, Kay R, Wong AH, Teoh R, and Nicholls MG. 1990. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. *Arch Neurol* 47:1174-1177.

Wu S, Wang C, Jia Q, Liu G, Hoff K, Wang X, Wang A, Wang C, Zhao X, Wang Y, Liu L, and Wang Y. 2014. HbA1c is associated with increased all-cause mortality in the first year after acute ischemic stroke. *Neuroir Res* 36:444-452. 10.1179/1743132814Y.0000000355

Yao M, Ni J, Zhou L, Peng B, Zhu Y, Cui L, and investigators S. 2016. Elevated Fasting Blood Glucose Is Predictive of Poor Outcome in Non-Diabetic Stroke Patients: A Sub-Group Analysis of SMART. *PLoS One* 11:e0160674. 10.1371/journal.pone.0160674
Figure Legend

Receiver operating characteristic (ROC) curves of admission random glucose, fasting glucose, and HbA1c for predicting poor neurological outcomes (modified Rankin Scale = 3, 4, or 5 at 3 months) in (A) all study patients, (B) nondiabetic patients, and (C) patients with diabetes

* p < 0.05
Receiver operating characteristic (ROC) curves of admission random glucose, fasting glucose, and HbA1c for predicting poor neurological outcomes (modified Rankin Scale = 3, 4, or 5 at 3 months) in (A) all study patients, (B) nondiabetic patients, and (C) patients with diabetes. * $p < 0.05$
Table 1. Clinical characteristics of the patients
|                                | Total patients (n=484) | Nondiabetic patients (n=212) | Diabetic patients (n=272) | p value |
|--------------------------------|------------------------|-------------------------------|---------------------------|---------|
| Age, mean ± SD, years          | 67.9 ± 13.7            | 65.9 ± 15.3                   | 69.5 ± 12.2               | 0.004*  |
| Male sex, n (%)                | 315 (65.1%)            | 145 (68.4%)                   | 170 (62.5%)               | 0.177   |
| Comorbidities, n (%)           |                        |                               |                           |         |
| Hypertension                   | 346 (71.5%)            | 132 (62.3%)                   | 214 (78.7%)               | <0.001* |
| Diabetes                       | 272 (56.2%)            | 0 (0%)                        | 212 (100%)                | N.A.    |
| Hyperlipidemia                 | 147 (30.4%)            | 62 (29.2%)                    | 85 (31.2%)                | 0.635   |
| Atrial fibrillation            | 74 (15.3%)             | 38 (17.9%)                    | 36 (13.2%)                | 0.155   |
| NIHSS at admission, median (IQR)| 4 (2 - 8)              | 4 (2 - 8)                     | 4 (2 - 7)                 | 0.972   |
| mRS at 3 months, median (IQR)  | 1 (1 - 2)              | 1 (1 - 2)                     | 1 (1 - 3)                 | 0.654   |
| poor neurological outcome, n (%)| 118 (24.4%)            | 48 (22.6%)                    | 70 (25.7%)                | 0.432   |
| Stroke etiology subtypes, n(%) |                        |                               |                           | 0.658   |
| Large artery atherosclerosis   | 133 (27.5%)            | 56 (26.4%)                    | 77 (28.3%)                |         |
| Small artery occlusion         | 166 (34.3%)            | 69 (32.5%)                    | 97 (35.7%)                |         |
| cardioembolism                 | 26 (5.4%)              | 12 (5.7%)                     | 14 (5.1%)                 |         |
| other determined etiology      | 1 (0.2%)               | 1 (0.5%)                      | 0 (0%)                    |         |
| undermined etiology            | 158 (32.6%)            | 74 (34.9%)                    | 84 (30.9%)                |         |
| Admission random glucose, mean ± SD, mg/dL | 175.5 ± 86.8 | 129.5 ± 34.8 | 211.4 ± 97.6 | <0.001* |
| fasting glucose, mean ± SD, mg/dL | 132.9 ± 58.7 | 102.1 ± 19.9 | 156.9 ± 67.3 | <0.001* |
| HbA1c, mean ± SD, % | 7.0 ±1.8 | 5.8 ±0.4 | 8.0 ±1.8 | <0.001* |

* p<0.05, IQR: interquartile range, SD, standard deviation
Table 2 (on next page)

Table 2. Univariate and multivariate logistic regression analyses of clinical characteristics and glycemic measures to poor neurological outcome
Table 2. Univariate and multivariate logistic regression analyses of clinical characteristics and glycemic measures to poor neurological outcome

| Characteristics | All patients (n = 484) | Nondiabetic patients (n = 212) |
|-----------------|------------------------|-------------------------------|
|                 | Crude OR (95% CI)      | p value | Adjusted OR model 1 (95% CI) | p value | Adjusted OR model 2 (95% CI) | p value | Adjusted OR model 3 (95% CI) | p value |
| Age             | 1.059 (1.040 - 1.080)  | <0.001* | 1.056 (1.032 - 1.080)        | <0.001* | 1.059 (1.034 - 1.084)        | <0.001* | 1.059 (1.034 - 1.084)        | <0.001* |
| Male sex        | 0.755 (0.492 - 1.159)  | 0.199   | 0.816 (0.472 - 1.411)        | 0.467   | 0.811 (0.468 - 1.404)        | 0.453   | 0.833 (0.481 - 1.443)        | 0.515   |
| NIHSS at admission | 1.320 (1.246 - 1.398) | <0.001* | 1.313 (1.237 - 1.395)        | <0.001* | 1.312 (1.235 - 1.392)        | <0.001* | 1.319 (1.241 - 1.402)        | <0.001* |
| Hypertension    | 1.159 (0.726 - 1.851)  | 0.535   | 1.387 (0.679 - 2.833)        | 0.370   | 1.373 (0.668 - 2.822)        | 0.388   | 1.452 (0.706 - 2.986)        | 0.311   |
| Hyperlipidemia  | 0.768 (0.482 - 1.223)  | 0.266   | 1.002 (0.999 - 1.004)        | 0.158   | 1.002 (0.999 - 1.005)        | 0.228   | 1.005 (1.003 - 1.010)        | 0.039*   |
| Atrial fibrillation | 2.870 (1.710 - 4.817) | 0.001*  | 1.347 (1.231 - 1.473)        | <0.001* | 1.345 (1.220 - 1.482)        | <0.001* | 1.396 (1.232 - 1.500)        | <0.001* |
| Admission random glucose | 1.002 (0.999 - 1.004) | 0.158   | 1.002 (0.999 - 1.005)        | 0.228   | 1.005 (1.003 - 1.010)        | 0.039*   | 1.160 (0.985 - 1.366)        | 0.076   |
| Fasting glucose | 1.005 (1.002 - 1.008)  | 0.003*  | 1.000 (1.003 - 1.010)        | 0.039*   | 1.005 (1.003 - 1.010)        | 0.039*   | 1.160 (0.985 - 1.366)        | 0.076   |
| HbA1c           | 1.032 (0.919 - 1.158)  | 0.600   | 1.032 (0.919 - 1.158)        | 0.600   | 1.032 (0.919 - 1.158)        | 0.600   | 1.160 (0.985 - 1.366)        | 0.076   |
### Diabetic patients (n = 272)

| Characteristics             | Crude OR (95% CI)       | p value | Adjusted OR model 1 (95% CI) | p value | Adjusted OR model 2 (95% CI) | p value | Adjusted OR model 3 (95% CI) | p value |
|-----------------------------|-------------------------|---------|-----------------------------|---------|-----------------------------|---------|-----------------------------|---------|
| Age                         | 1.057 (1.030 - 1.086)   | <0.001* | 1.049 (1.017 - 1.082)       | 0.002*  | 1.053 (1.021 - 1.087)       | 0.001*  | 1.055 (1.021 - 1.109)       | 0.001*  |
| Male sex                    | 0.867 (0.497 - 1.514)   | 0.616   | 0.892 (0.445 - 1.788)       | 0.747   | 0.873 (0.434 - 1.755)       | 0.703   | 0.914 (0.455 - 1.837)       | 0.801   |
| NIHSS at admission          | 1.304 (1.209 - 1.407)   | <0.001* | 1.291 (1.194 - 1.395)       | <0.001* | 1.286 (1.190 - 1.389)       | <0.001* | 1.295 (1.197 - 1.400)       | <0.001* |
| Hypertension                | 1.257 (0.632 - 2.500)   | 0.515   |                             |         |                             |         |                             |         |
| Hyperlipidemia              | 0.843 (0.464 - 1.531)   | 0.575   |                             |         |                             |         |                             |         |
| Atrial fibrillation         | 3.089 (1.500 - 6.361)   | 0.002*  | 1.436 (0.527 - 3.915)       | 0.480   | 1.361 (0.493 - 3.761)       | 0.552   | 1.496 (0.545 - 4.111)       | 0.435   |
| Admission random glucose    | 1.001 (0.999 - 1.004)   | 0.319   | 1.002 (0.998 - 1.006)       | 0.319   |                             |         |                             |         |
| Fasting glucose             | 1.004 (1.001 - 1.008)   | 0.003*  | 1.005 (0.999 - 1.010)       | 0.110   |                             |         |                             |         |
| HbA1c                       | 1.000 (0.863 - 1.161)   | 0.992   |                             |         |                             |         |                             |         |

* p<0.05, OR: odds ratio

- model 1 included age, sex, NIHSS at admission, atrial fibrillation, and admission random glucose
- model 2 included age, sex, NIHSS at admission, atrial fibrillation, and fasting glucose
- model 3 included age, sex, NIHSS at admission, atrial fibrillation, and HbA1c